|
注册号: Registration number: |
ChiCTR2600120813 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-20 08:22:55 |
|
注册时间: Date of Registration: |
2026-03-20 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
口腔及胃微生物谱预测自身免疫性胃炎及HP相关胃炎的多态性模型 |
|
Public title: |
Polymorphism models based on oral and gastric microbiome profiles for predicting autoimmune gastritis and Helicobacter pylori–associated gastritis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
口腔及胃微生物谱预测自身免疫性胃炎及HP相关胃炎的多态性模型 |
|
Scientific title: |
Polymorphism models based on oral and gastric microbiome profiles for predicting autoimmune gastritis and Helicobacter pylori–associated gastritis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
邹芳蕊 |
研究负责人: |
周晓颖 |
|
Applicant: |
Fangrui Zou |
Study leader: |
Xiaoying Zhou |
|
申请注册联系人电话: Applicant telephone: |
+86 159 9694 9736 |
研究负责人电话:
Study leader's |
+86 158 5066 8395 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zoufangrui1112@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhouxiaoying0926@njmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市鼓楼区广州路300号 |
研究负责人通讯地址: |
江苏省南京市鼓楼区广州路300号 |
|
Applicant address: |
300 Guangzhou Road, Gulou District, Nanjing, Jiangsu |
Study leader's address: |
300 Guangzhou Road, Gulou District, Nanjing, Jiangsu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
江苏省人民医院 |
||
|
Applicant's institution: |
Jiangsu Province Hospital |
||
|
研究负责人所在单位: |
江苏省人民医院 |
||
|
Affiliation of the Leader: |
Jiangsu Province Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-SR-640 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京医科大学第一附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Nanjing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-04 00:00:00 | ||
|
伦理委员会联系人: |
张馥敏 |
||
|
Contact Name of the ethic committee: |
Zhang Fumin |
||
|
伦理委员会联系地址: |
江苏南京市鼓楼区广州路300号下· |
||
|
Contact Address of the ethic committee: |
300 Guangzhou Road, Gulou District, Nanjing, Jiangsu |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 6830 6360 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
江苏省人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jiangsu Province Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏南京市鼓楼区广州路300号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
300 Guangzhou Road, Gulou District, Nanjing, Jiangsu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
N/A |
||||||||||||||||||||||
|
研究疾病: |
自身免疫性胃炎 |
||||||||||||||||||||||
|
Target disease: |
autoimmune gastritis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1.探讨自身免疫性胃炎与口腔及胃微生物群的相关性,探寻有助于早期诊断自身免疫性胃炎的微生物标志物。 2.通过对比自身免疫性胃炎患者、幽门螺杆菌(H. pylori)相关萎缩性胃炎患者以及健康对照人群的口腔和胃微生物群组成,明确不同人群中口腔和胃微生物群的差异特征。 3.探究口腔微生物群的变化对胃黏膜的微生态的影响,以及两者的相互作用对自身免疫性胃炎的影响。 4.结合口腔及胃微生物群、血清学、内镜表现、病理表现,构建自身免疫性胃炎的早期诊断模型。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To investigate the association between autoimmune gastritis and the oral and gastric microbiota, and to identify microbial biomarkers that may facilitate the early diagnosis of autoimmune gastritis. (2) To compare the composition of the oral and gastric microbiota among patients with autoimmune gastritis, patients with Helicobacter pylori (H. pylori)–associated atrophic gastritis, and healthy controls, in order to characterize the distinct microbial features of different populations. (3) To explore the impact of alterations in the oral microbiota on the gastric mucosal microecology, and to elucidate how their interactions contribute to the development of autoimmune gastritis. (4) To construct an early diagnostic model for autoimmune gastritis by integrating oral and gastric microbiota profiles with serological findings, endoscopic features, and histopathological characteristics. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
【自身免疫性胃炎排除标准】 (1)既往有上消化道手术史,或接受过抗肿瘤治疗史; (2)年龄小于18岁; (3)最近6个月内接受免疫抑制剂或抗生素或益生菌治疗超过4周; (4)近期口腔感染、炎症、脓疱、溃疡、良/恶性包块、牙周病等口腔病史; (5)各种原因引起的牙齿缺失8 颗牙齿以上者; (6)既往有复杂食管病、炎症性肠病、血液病或风湿性自身免疫性疾病史; (7)难以完成随访或存在影响依从性的其他因素; 【HP相关萎缩性胃炎排除标准】 (1)既往有上消化道手术史,或接受过抗肿瘤治疗史; (2)年龄小于18岁; (3)最近6个月内接受免疫抑制剂或抗生素或益生菌治疗超过4周; (4)近期口腔感染、炎症、脓疱、溃疡、良/恶性包块、牙周病等口腔病史; (5)各种原因引起的牙齿缺失8 颗牙齿以上者; (6)既往有复杂食管病、炎症性肠病、血液病或风湿性自身免疫性疾病史; (7)难以完成随访或存在影响依从性的其他因素; 【健康对照组排除标准】 (1)存在内镜下报告的病变,如萎缩性胃炎、反流性食管炎、上消化道肿瘤、发育不良、溃疡、糜烂和粘膜下病变等; (2)拒绝提供唾液和胃活检标本; (3)年龄小于18岁; (4)在过去6个月内使用免疫抑制剂或抗生素或益生菌治疗超过4周; (5)最近有感染、炎症、脓疱、溃疡、良性/恶性肿块、牙周病的口述史; (6)各种原因引起的牙齿缺失8 颗牙齿以上者; (7)既往有复杂食管病、炎症性肠病、血液病或风湿性自身免疫性疾病史; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Exclusion Criteria for Autoimmune Gastritis : (1) History of upper gastrointestinal surgery, or prior antitumor therapy; (2) Age < 18 years; (3) Use of immunosuppressants, antibiotics, or probiotics for more than 4 weeks within the past 6 months; (4) Recent history of oral diseases, including oral infection, inflammation, pustules, ulcers, benign or malignant oral masses, periodontal disease, or other oral conditions; (5) Loss of more than 8 teeth due to any cause; (6) History of complicated esophageal diseases, inflammatory bowel disease, hematologic disorders, or rheumatic autoimmune diseases; (7) Inability to complete follow-up or presence of other factors affecting treatment compliance. 2.Exclusion Criteria for H. pylori–Associated Atrophic Gastritis (1) History of upper gastrointestinal surgery, or prior antitumor therapy ; (2) Age < 18 years; (3) Use of immunosuppressants, antibiotics, or probiotics for more than 4 weeks within the past 6 months; (4) Recent history of oral diseases, including oral infection, inflammation, pustules, ulcers, benign or malignant oral masses, periodontal disease, or other oral conditions; (5) Loss of more than 8 teeth due to any cause; (6) History of complicated esophageal diseases, inflammatory bowel disease, hematologic disorders, or rheumatic autoimmune diseases; (7) Inability to complete follow-up or presence of other factors affecting treatment compliance. 3.Exclusion Criteria for Healthy Controls: (1) Presence of endoscopically confirmed lesions, including atrophic gastritis, reflux esophagitis, upper gastrointestinal tumors, dysplasia, ulcers, erosions, or submucosal lesions; (2) Refusal to provide saliva and gastric biopsy specimens; (3) Age < 18 years; (4) Use of immunosuppressants, antibiotics, or probiotics for more than 4 weeks within the past 6 months; (5) Recent self-reported history of oral infection, inflammation, pustules, ulcers, benign/malignant oral masses, periodontal disease, or other oral conditions; (6) Loss of more than 8 teeth due to any cause; (7) History of complicated esophageal diseases, inflammatory bowel disease, hematologic disorders, or rheumatic autoimmune diseases. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-11-10 00:00:00至 To 2026-11-10 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-11-16 00:00:00 至 To 2026-11-10 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
所有扩增子原始数据将会提交至国家生物信息中心(CNCB,https://cncb.ac.cn/)的组学原始数据归档库(Genome Sequence Archive, GSA)。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
All raw amplicon sequencing data will be submitted to the Genome Sequence Archive (GSA) at the National Genomics Data Center, China National Center for Bioinformation (CNCB, https://cncb.ac.cn/). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Use a medical record sheet |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |